Therapy Areas: Inflammatory Diseases
Modulus Discovery Closes USD 25.5m Series B
14 May 2020 - - Japan-based preclinical-stage technology-driven drug discovery firm Modulus Discovery, Inc has closed its series B funding round in the amount of JPY 2.71bn (approximately USD 25.5m), the company said.

Series B investors include SBI Investments Co., Ltd., Mizuho Capital Co., Ltd., JAFCO Co., Ltd., Keio Innovation Initiative, Inc., SMBC Venture Capital Co., Ltd., The Dai-ichi Life Insurance company, Ltd., UTokyo Innovation Platform Co., Ltd., Mobile Internet Capital, Inc., Medifuture, Co., Ltd., Essential Pharma, Co., Ltd., and existing shareholder, Fast Track Initiative, Inc. Modulus has raised to date, a total of 3.51B JPY (approximately USD 33.1m) across its series A and B rounds.

Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.

Modulus Discovery, Inc., is a preclinical-stage technology-driven drug discovery firm with offices in Tokyo and Boston.

The company is pursuing its proprietary portfolio of small-molecule discovery programs and collaborations through integration of its unique core biology insights, cutting-edge discovery platform, and scalable networked operations.

Modulus is focused on the efficient delivery of breakthrough medicines for patients and their families with unmet medical needs in areas including oncology, chronic inflammation / immune disorders, and rare genetic conditions.
Login
Username:

Password: